Synovus Financial Corp increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.2% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 58,403 shares of the biopharmaceutical company’s stock after buying an additional 2,375 shares during the quarter. Synovus Financial Corp’s holdings in Halozyme Therapeutics were worth $898,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in HALO. NumerixS Investment Technologies Inc boosted its position in Halozyme Therapeutics by 70.7% in the second quarter. NumerixS Investment Technologies Inc now owns 2,390 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 990 shares during the last quarter. Steward Partners Investment Advisory LLC purchased a new position in Halozyme Therapeutics in the second quarter worth about $49,000. Ladenburg Thalmann Financial Services Inc. boosted its position in Halozyme Therapeutics by 25.2% in the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 967 shares during the last quarter. EP Wealth Advisors LLC purchased a new position in Halozyme Therapeutics in the second quarter worth about $172,000. Finally, Quantamental Technologies LLC purchased a new position in Halozyme Therapeutics in the second quarter worth about $173,000. Institutional investors own 82.50% of the company’s stock.
Shares of HALO stock traded up $0.12 during trading hours on Friday, reaching $16.86. 9,335 shares of the company traded hands, compared to its average volume of 1,258,322. Halozyme Therapeutics, Inc. has a 12-month low of $13.24 and a 12-month high of $17.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 2.57. The company has a market cap of $2.50 billion, a P/E ratio of -30.23 and a beta of 1.78. The firm has a 50-day moving average price of $15.69 and a 200 day moving average price of $16.13.
Several research analysts have issued reports on the company. ValuEngine cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Barclays raised Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and dropped their target price for the stock from $17.00 to $16.00 in a research report on Tuesday. BidaskClub cut Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a research report on Thursday. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $20.50.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Story: Mutual Funds
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.